Stonehaven Incubate and Nuritas announced July 23 a new collaboration in which they will join forces as part of a newly created joint venture that will use cutting-edge artificial intelligence technology to discover and develop advanced animal health solutions, with an initial focus on exploring feed ingredients.
Stonehaven Incubate is a dedicated animal health group committed to creating new companies de novo from disruptive human technology, the announcement said, while Nuritas combines artificial intelligence and genomics to discover and unlock natural bioactive peptides with health benefits.
Stonehaven Incubate chief executive officer Dr. Mark Heffernan said, “We see working with Nuritas on the use of its artificial intelligence platform to identify bioactive peptides as novel animal health solutions. The initial phase of our work together will include establishing a new company focused on this platform for animal health and conducting a series of evaluation trials.”
Nuritas CEO Emmet Browne added, “This partnership will deliver a unique and winning edge in this space by pairing Stonehaven Incubate’s deep industry specific understanding and experience with Nuritas’ ground-breaking technology. The formation of the new company will enable us to focus on adding significant value to existing Nuritas discoveries in the field of animal health, in addition to partnering externally on specific ground-breaking new projects.
"We have already experienced significant success with our unique discovery platform in the human world, and now we are delighted to complement this with truly game-changing collaborations in the animal world,” Browne said.
Switzerland-based Stonehaven Incubate, formed in February 2018, works with innovators and builds strategies for stand-alone new animal health companies. Its parent company, Stonehaven Holding was formed in 2017 by former Novartis AG executives George Gunn and Matthias Hofer.